MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Home・Aandelen Lijst・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Gesloten

SectorGezondheidszorg

33.75 -0.21

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

33.24

Max

33.9

Belangrijke statistieken
By Trading Economics
Inkomsten	-14M -81M
Verkoop	75K 75K
EPS	-1.22
Winstmarge	-108,422.667
Werknemers	198
EBITDA	-7.8M -81M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+60.91% upside

Dividenden
By Dow Jones
Volgende Winsten	6 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	941M 2.6B
Vorige openingsprijs	33.96
Vorige sluitingsprijs	33.75

Nieuwssentiment

By Acuity

100%

337 / 348 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

18.91 / 20.63 Steun & Weerstand

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

16 apr 2026, 23:26 UTC

Populaire aandelen

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16 apr 2026, 20:41 UTC

Belangrijke Marktbewegers

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16 apr 2026, 23:49 UTC

Marktinformatie

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16 apr 2026, 23:45 UTC

Marktinformatie

Nikkei May Decline After Hitting Record High -- Market Talk

16 apr 2026, 23:33 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16 apr 2026, 22:51 UTC

Marktinformatie

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16 apr 2026, 22:08 UTC

Winsten

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16 apr 2026, 22:06 UTC

Winsten

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16 apr 2026, 22:06 UTC

Winsten

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16 apr 2026, 22:06 UTC

Winsten

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16 apr 2026, 22:06 UTC

Winsten

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16 apr 2026, 22:06 UTC

Winsten

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16 apr 2026, 20:50 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

16 apr 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

16 apr 2026, 20:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

16 apr 2026, 20:50 UTC

Marktinformatie

Winsten

Health Care Roundup: Market Talk

16 apr 2026, 20:49 UTC

Winsten

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16 apr 2026, 20:43 UTC

Winsten

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 apr 2026, 20:40 UTC

Marktinformatie

Winsten

Global Equities Roundup: Market Talk

16 apr 2026, 20:40 UTC

Marktinformatie

Winsten

Netflix Says Engagement Quality Hits New High -- Market Talk

16 apr 2026, 20:30 UTC

Populaire aandelen

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16 apr 2026, 20:25 UTC

Winsten

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 apr 2026, 20:23 UTC

Winsten

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16 apr 2026, 20:19 UTC

Winsten

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16 apr 2026, 20:17 UTC

Winsten

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16 apr 2026, 20:17 UTC

Winsten

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16 apr 2026, 20:16 UTC

Winsten

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16 apr 2026, 20:16 UTC

Winsten

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16 apr 2026, 20:16 UTC

Winsten

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16 apr 2026, 20:16 UTC

Winsten

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

60.91% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 54.5 USD 60.91%

Hoogste 90 USD

Laagste 24 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Celldex Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.